Joanna Robson1, Helen Doll2, Ravi Suppiah3, Oliver Flossmann4, Lorraine Harper5, Peter Höglund6, David Jayne7, Alfred Mahr8, Kerstin Westman9, Raashid Luqmani10. 1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NDORMs), University of Oxford, Oxford, USA Rheumatology Department, Nuffield Orthopaedic Centre, Oxford, UK. 2. Department of Population Health, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK. 3. Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand. 4. Renal Department, Royal Berkshire NHS Foundation Trust, Reading, UK. 5. School of Immunity and Infection, Centre for Translational Inflammation Research, University of Birmingham, Birmingham, UK. 6. Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden. 7. Renal Department, Addenbrooke's Hospital, Cambridge, UK. 8. Department of Internal Medicine, Hospital Saint-Louis, Paris, France. 9. Nephrology and Transplantation, Skane University Hospital Malmo, Lund University, Malmo, Sweden. 10. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NDORMs), University of Oxford, Oxford, USA.
Abstract
OBJECTIVES: To describe short-term (up to 12 months) and long-term (up to 7 years) damage in patients with newly diagnosed antineutrophil-cytoplasm antibody-associated vasculitis (AAV). METHODS: Data were combined from six European Vasculitis Study group trials (n=735). Long-term follow-up (LTFU) data available for patients from four trials (n=535). Damage accrued was quantified by the Vasculitis Damage Index (VDI). Sixteen damage items were defined a priori as being potentially treatment-related. RESULTS: VDI data were available for 629 of 735 patients (85.6%) at baseline, at which time 217/629 (34.5%) had ≥1 item of damage and 32 (5.1%) ≥5 items, reflecting disease manifestations prior to diagnosis and trial enrolment. LTFU data were available for 467/535 (87.3%) at a mean of 7.3 years postdiagnosis. 302/535 patients (56.4%) had VDI data at LTFU, with 104/302 (34.4%) having ≥5 items and only 24 (7.9%) no items of damage. At 6 months and LTFU, the most frequent items were proteinuria, impaired glomerular filtration rate, hypertension, nasal crusting, hearing loss and peripheral neuropathy. The frequency of damage, including potentially treatment-related damage, rose over time (p<0.01). At LTFU, the most commonly reported items of treatment-related damage were hypertension (41.5%; 95% CI 35.6 to 47.4%), osteoporosis (14.1%; 9.9 to 18.2%), malignancy (12.6%; 8.6 to 16.6%), and diabetes (10.4%; 6.7 to 14.0%). CONCLUSIONS: In AAV, renal, otolaryngological and treatment-related (cardiovascular, disease, diabetes, osteoporosis and malignancy) damage increases over time, with around one-third of patients having ≥5 items of damage at a mean of 7 years postdiagnosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVES: To describe short-term (up to 12 months) and long-term (up to 7 years) damage in patients with newly diagnosed antineutrophil-cytoplasm antibody-associated vasculitis (AAV). METHODS: Data were combined from six European Vasculitis Study group trials (n=735). Long-term follow-up (LTFU) data available for patients from four trials (n=535). Damage accrued was quantified by the Vasculitis Damage Index (VDI). Sixteen damage items were defined a priori as being potentially treatment-related. RESULTS: VDI data were available for 629 of 735 patients (85.6%) at baseline, at which time 217/629 (34.5%) had ≥1 item of damage and 32 (5.1%) ≥5 items, reflecting disease manifestations prior to diagnosis and trial enrolment. LTFU data were available for 467/535 (87.3%) at a mean of 7.3 years postdiagnosis. 302/535 patients (56.4%) had VDI data at LTFU, with 104/302 (34.4%) having ≥5 items and only 24 (7.9%) no items of damage. At 6 months and LTFU, the most frequent items were proteinuria, impaired glomerular filtration rate, hypertension, nasal crusting, hearing loss and peripheral neuropathy. The frequency of damage, including potentially treatment-related damage, rose over time (p<0.01). At LTFU, the most commonly reported items of treatment-related damage were hypertension (41.5%; 95% CI 35.6 to 47.4%), osteoporosis (14.1%; 9.9 to 18.2%), malignancy (12.6%; 8.6 to 16.6%), and diabetes (10.4%; 6.7 to 14.0%). CONCLUSIONS: In AAV, renal, otolaryngological and treatment-related (cardiovascular, disease, diabetes, osteoporosis and malignancy) damage increases over time, with around one-third of patients having ≥5 items of damage at a mean of 7 years postdiagnosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Disease Activity; Epidemiology; Granulomatosis with polyangiitis; Outcomes research; Treatment
Authors: Peiqi Hu; Hua Su; Hong Xiao; Shen-Ju Gou; Carolina A Herrera; Marco A Alba; Masao Kakoki; Ronald J Falk; J Charles Jennette Journal: J Am Soc Nephrol Date: 2019-11-26 Impact factor: 10.121
Authors: Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig Journal: Z Rheumatol Date: 2017-11 Impact factor: 1.372
Authors: Joanna C Robson; Gunnar Tomasson; Nataliya Milman; Sue Ashdown; Annelies Boonen; George C Casey; Peter F Cronholm; David Cuthbertson; Jill Dawson; Haner Direskeneli; Ebony Easley; Tanaz A Kermani; John T Farrar; Don Gebhart; Georgia Lanier; Raashid A Luqmani; Alfred Mahr; Carol A McAlear; Jacqueline Peck; Beverley Shea; Judy A Shea; Antoine G Sreih; Peter S Tugwell; Peter A Merkel Journal: J Rheumatol Date: 2017-09-01 Impact factor: 4.666
Authors: Tanaz A Kermani; Antoine G Sreih; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Paul A Monach; Larry Moreland; Christian Pagnoux; Philip Seo; Kenneth J Warrington; Steven R Ytterberg; Peter A Merkel Journal: Rheumatology (Oxford) Date: 2018-02-01 Impact factor: 7.580
Authors: Joanna C Robson; Nataliya Milman; Gunnar Tomasson; Jill Dawson; Peter F Cronholm; Katherine Kellom; Judy Shea; Susan Ashdown; Maarten Boers; Annelies Boonen; George C Casey; John T Farrar; Don Gebhart; Jeffrey Krischer; Georgia Lanier; Carol A McAlear; Jacqueline Peck; Antoine G Sreih; Peter S Tugwell; Raashid A Luqmani; Peter A Merkel Journal: J Rheumatol Date: 2015-09-01 Impact factor: 4.666